This web page is made to ease judges the review of medal criteria. We hope to have a good harvest of GOID MEDAL after summer.
Registration and Giant Jamboree Attendance
Our team application was sent on 2019/02/23 and was accepted on 2019/03/27 as we can see in this link: iGEM TJUSLS_China registration. We will appear on time at Giant Jamboree Attendance.
Wiki/Poster/Presentation:The wiki page was finalized on 21 October as the deadline indicated. The poster and the presentation will be shown in the Giant Jamboree.
Judging form: Judging form was submited on 16 october and is visible for judges since that deadline. For more information, check out our Judging Form.
To visibilize attributions with the importance it deserves we made an special web page, visit it in the Attributions page, in which we have 3 parts, iGEM course, team work and acknowledgement.
Project Inspiration and Description
We have recorded our project inspiration and description in detail, please refer to Description page for details.
We have added quantitative experimental characterization data to an existing Part from the Registry of Standard Biological Parts. Please see the Parts page for more information about experimental characterization data.
We provided 20 beta-lactamase genes and modified each gene by adding different components to improve their expression. Our three validated parts is the BBa_K2933002, BBa_K2933004, BBa_K2933025 basic DNA piece.
iGEM would not be what it is whithout interaction between teams. We have done six collaborations during all this summer. To check out what we have done please go to our collaborations page.
We consider Human Practices as a part of test in Design-Build-Test circle. Advice from professors and voices from partners make contribution to test flexibility of and debug our project. This circle ends up as convincing potential demonstration of MBLs' new inhibitor.To see more, please go to: Human Practices .
Integrated Human Practices
The way we used our Human Practices work to improve and adapt our project can be read in the next link: Human Practices.
Improve a Previous Part
We registered a new part BBa_K2933285 which is an improvement of the exsiting part BBa_K2328027 used in our team from previous years. smURFP (small ultra-red FP) is a type of fluorescent protein. In order to produce fluoresce, smURFP must be combined with biliverdin (BV).This year we want to mutate the protein and enhance its BV binding ability by modifying its sequence.For more information, check out our Improve page .
Modeling is one of the central axes of Inhibitor screening. We built a multistep virtual screening model to discover the therapeutically effective components, which were used to predict potential inhibitors. The model is meant to provide the lab with a rather narrow range of compounds to conduct experiments on. Want to see more? Check out the Modeling page.
We have transfered the parts we constructed into living E.coil to evaluate therapeutic effect. It has shown that our parts work well in real conditions. You can check it going to the Demonstrate page.